Erlotinib combined with cyclosporine in a liver-transplant recipient with epidermal growth factor receptor-mutated non-small cell lung cancer.
De Pas
Tommaso
T
Spitaleri
Gianluca
G
Pelosi
Giuseppe
G
De Carlis
Luciano
L
Lorizzo
Katia
K
Locatelli
Marzia
M
Curigliano
Giuseppe
G
Toffalorio
Francesca
F
Catania
Chiara
C
de Braud
Filippo
F
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D016572:Cyclosporine / Q000008:administration & dosage*; D066246:ErbB Receptors / Q000235:genetics*; D000069347:Erlotinib Hydrochloride; D006801:Humans; D016031:Liver Transplantation; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D011799:Quinazolines / Q000008:administration & dosage
D011799:Quinazolines; D016572:Cyclosporine; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors